Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) Short Interest Update

Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) saw a significant drop in short interest in July. As of July 15th, there was short interest totaling 49,784 shares, a drop of 39.9% from the June 30th total of 82,827 shares. Approximately 1.1% of the company’s stock are short sold. Based on an average trading volume of 87,989 shares, the short-interest ratio is currently 0.6 days.

Sonoma Pharmaceuticals Trading Up 2.7%

Shares of SNOA opened at $1.13 on Friday. The firm has a market cap of $5.41 million, a price-to-earnings ratio of -0.60 and a beta of 1.27. Sonoma Pharmaceuticals has a 52 week low of $0.85 and a 52 week high of $6.92. The stock has a 50 day moving average of $1.16 and a 200-day moving average of $1.96.

Sonoma Pharmaceuticals (NASDAQ:SNOA) last announced its quarterly earnings data on Tuesday, June 16th. The company reported ($0.33) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.24) by ($0.09). The firm had revenue of $5.56 million for the quarter, compared to the consensus estimate of $5.57 million. Sonoma Pharmaceuticals had a negative return on equity of 43.95% and a negative net margin of 16.26%.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Sonoma Pharmaceuticals in a research report on Friday, July 24th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, Sonoma Pharmaceuticals currently has an average rating of “Sell”.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Sonoma Pharmaceuticals stock. McKinley Carter Wealth Services Inc. acquired a new stake in shares of Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 11,193 shares of the company’s stock, valued at approximately $41,000. McKinley Carter Wealth Services Inc. owned about 0.66% of Sonoma Pharmaceuticals as of its most recent SEC filing. 1.95% of the stock is currently owned by hedge funds and other institutional investors.

About Sonoma Pharmaceuticals

Sonoma Pharmaceuticals, Inc is a specialty dermatology company focused on developing and commercializing topical prescription and over-the-counter products for inflammatory and infectious skin conditions. Publicly traded on Nasdaq under the symbol SNOA, the company concentrates its efforts on areas such as acne, rosacea, dermatitis and wound care, aiming to provide physicians and patients with innovative treatment options.

At the heart of Sonoma’s technology platform lies its proprietary Triphasic drug delivery system, which enables the timed release of active ingredients through three distinct gel phases.